Brentuximab Vedotin Prevention of (GVHD) After Unrelated Allogeneic Stem Cell Transplantation
Status:
Completed
Trial end date:
2016-11-21
Target enrollment:
Participant gender:
Summary
This pilot clinical trial studies the safety and maximum tolerated dose of brentuximab
vedotin when given with tacrolimus and methotrexate after unrelated allogeneic donor stem
cell transplant in patients with acute myeloid leukemia, acute lymphoblastic leukemia, or
myelodysplastic syndromes. The addition of brentuximab vedotin to tacrolimus and methotrexate
may result in a significant reduction of graft versus host disease in these patients.